ENLV Enlivex Therapeutics Ltd

Price (delayed)

$0.5459

Market cap

$129.59M

P/E Ratio

0.02

Dividend/share

N/A

EPS

$27.04

Enterprise value

$124.21M

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: 94
Relative Profitability: Rel. Profitability: 64

enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib ...

Highlights
ENLV's debt is up by 28% YoY

Key stats

What are the main financial stats of ENLV

ENLV stock price

How has the Enlivex Therapeutics stock price performed over time
Intraday
-5.88%
1 week
-10.63%
1 month
-32.63%
1 year
-51.26%
YTD
-22.37%
QTD
-41.31%

Financial performance

How have Enlivex Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.03M
Net income
$1.24B
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 5% YoY

Price vs fundamentals

How does ENLV's price correlate with its fundamentals

Growth

What is Enlivex Therapeutics's growth rate over time

Valuation

What is Enlivex Therapeutics stock price valuation
P/E
0.02
P/B
0.01
P/S
N/A
EV/EBIT
0.08
EV/EBITDA
0.08
EV/Sales
N/A
ENLV's P/B is 99% below its 5-year quarterly average of 1.3 and 99% below its last 4 quarters average of 1.0

Efficiency

How efficient is Enlivex Therapeutics business performance
The ROIC has soared by 148% YoY and by 103% from the previous quarter

Dividends

What is ENLV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENLV.

Financial health

How did Enlivex Therapeutics financials performed over time
ENLV's debt is 100% lower than its equity
The debt to equity has plunged by 100% YoY
ENLV's debt is up by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.